Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial-Reference-Cited by-同舟云学术

Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial

Published:2020-02-13 Issue:2 Volume:6 Page:e193332
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Dueck Amylou C.¹,Scher Howard I.²,Bennett Antonia V.³,Mazza Gina L.¹,Thanarajasingam Gita⁴,Schwab Gisela⁵,Weitzman Aaron L.⁶,Rogak Lauren J.⁷,Basch Ethan³

Affiliation:

1. Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona

2. Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

3. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

4. Division of Hematology, Mayo Clinic, Rochester, Minnesota

5. Exelixis Inc, South San Francisco, California

6. Independent Consultant, San Francisco, California

7. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2751871/jamaoncology_dueck_2019_br_190009.pdf

Reference10 articles.

1. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.;Basch;J Natl Cancer Inst,2009

2. Focusing on core patient-reported outcomes in cancer clinical trials—response.;Kluetz;Clin Cancer Res,2016

3. Development of the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).;Basch;J Natl Cancer Inst,2014

4. Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).;Hay;Qual Life Res,2014

5. Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).;Dueck;JAMA Oncol,2015

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Measuring Patient-Reported Outcomes (PROs) and Treatment Tolerability in Patients With Hematologic Malignancies;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Unleashing patient voices: empowering adverse event assessment with complete patient-reported outcomes;The Oncologist;2024-05-24

3. Adverse Events Reporting in Digital Interventions Evaluations for Psychosis: A Systematic Literature Search and Individual Level Content Analysis of Adverse Event Reports;Schizophrenia Bulletin;2024-04-06

4. Mitoxantrone encapsulated photosensitizer nanomicelle as carrier-free theranostic nanomedicine for near-infrared fluorescence imaging-guided chemo-photodynamic combination therapy on cancer;International Journal of Pharmaceutics;2024-04

5. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma;JAMA Network Open;2024-03-27